El papel de los ácidos grasos omega 3 en el manejo de enfermedades de tipo intestinal: una revisión narrativa

Luis César Reyes-Moreno

doi:10.35454/rncm.v6n4.544

Authors

Luis César Reyes-Moreno Hospital Starmedica Roma.

DOI:

https://doi.org/10.35454/rncm.v6n4.544

Keywords:

Fatty acids, Omega 3, Ulcerative Colitis, Inflammatory bowel disease, Colitis, Fish oil

Abstract

There are various bowel diseases that affect a large number of patients each year worldwide; therefore, establishing nutritional guidelines to provide a better living standard is currently a necessity.

The PUFA (polyunsaturated fatty acids) omega-3, in recent years, have been positively related to multiple diseases due to their anti-inflammatory function carried out by their specialized pro-resolving mediators. The objective of this narrative review is to collect information on the role of these molecules in some bowel diseases for evidence-based decision making and to provide recommendations regarding their use.

The information search was performed in databases of scientific literature in English and Spanish (Elsevier, Directory of Open Access Journals [DOAJ], PubMed, Springer Link, Medline), using the next Medical Subject Headings (MeSH) terms: “fatty acids”, “omega-3” , “fish oil”, “ulcerative colitis”, “docosahexaenoic acid”, “colitis”, “inflammatory bowel disease”, “bowel”.

The role of omega-3 fatty acids in bowel diseases remains unclear; further studies are required to determine its dose and timing, as well as the outcomes related to the use of this substance in these diseases.

Downloads

Download data is not yet available.

References

Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-22.doi: 10.25122/jml-2018-0075

Wang T, Liu K, Wen L, Yang Y, Yin X, Liu K, et al. Autophagy and Gastrointestinal Diseases. En: Le W (editor). Autophagy: Biology and Diseases. Springer; 2020. p. 529-56.

Balestrieri P, Ribolsi M, Guarino MPL, Emerenziani S, Altomare A, Cicala M. Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients. 2020;12(2):372.doi: 10.3390/nu12020372

Calder PC. Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc Nutr Soc. 2018;77(1):52-72. doi: 10.1017/S0029665117003950

Sharma T, Mandal CC. Omega-3 fatty acids in pathological calcification and bone health. J Food Biochem. 2020 ;44(8):e13333. doi: 10.1111/jfbc.13333

Michea MA, Briceño C, Alcota M, González FE. Péptidos antimicrobianos y mediadores lipídicos: rol en las enfermedades periodontales. Rev Clin Periodoncia Implantol Rehabil Oral. 2016;9(3):231-7. doi: 10.1016/j.piro.2016.03.003

Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med. 2021;21(2):135-9. doi: 10.7861/clinmed.2021-0080

Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. doi: 10.1016/S01406736(12)60150-0

Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, Pogodziński D. Nutrition and Supplementation in Ulcerative Colitis. Nutrients. 2022;14(12):2469. doi: 10.3390/nu14122469

Ajabnoor SM, Thorpe G, Abdelhamid A, Hooper L. Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2020;60(5):2293-316. doi: 10.1007/s00394-020-02413-y

Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(3):CD006443. doi: 10.1002/14651858.CD006443.pub2

Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MAM, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil ω-3 fatty acids. Nutrition. 2003;19(10):837-42. https://doi.org/10.1016/s0899-9007(03)00162-x

Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Enfermedad de Crohn. Med Clin (Barc). 2018;151(1):26-33. doi: 10.1016/j.medcli.2017.10.036

Veauthier B, Hornecker JR. Crohn’s Disease: Diagnosis and Management. Am Fam Physician. 2018;98(11):661-9.

Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct. 2020;15(1):23. doi: 10.1186/s13062-020-00280-5

Cushing K, Higgins PDR. Management of Crohn Disease: A Review. JAMA. 2021;325(1):69-80. doi: 10.1001/jama.2020.18936

Swan K, Allen PJ. Omega-3 fatty acid for the treatment and remission of Crohn’s disease. J Complement Integr Med. 2013;10:/j/jcim.2013.10.issue-1/jcim-2012-0010/jcim-2012-0010.xml. doi: 10.1515/jcim-2012-0010

Yasueda A, Shinzaki S, Iijima H, Mizushima T, Nishimura J, Hiyama S, et al. Safety of Emulsifying Lipid Formulation Containing Omega-3 Polyunsaturated Fatty Acids for Patients with Crohn’s Disease. Anticancer Res. 2016;36(7):3753-9.

Marton LT, Goulart RA, Carvalho ACA, Barbalho SM. Omega Fatty Acids and Inflammatory Bowel Diseases: An Overview. Int J Mol Sci. 2019;20(19):4851. doi: 10.3390/ijms20194851

Bavaro MF. Neutropenic enterocolitis. Curr Gastroenterol Rep. 2002;4(4):297-301. doi: 10.1007/s11894-002-0079-y

Xia R, Zhang X. Neutropenic enterocolitis: A clinico-pathological review. World J Gastrointest Pathophysiol. 2019;10(3):36–41. doi: 10.4291/wjgp.v10.i3.36

Davila ML. Neutropenic enterocolitis. Curr Opin Gastroenterol. 2006;22(1):44-7.doi: 10.1097/01.mog.0000198073.14169.3b

Bükki J, Stanga Z, Tellez FB, Duclos K, Kolev M, Krähenmann P, et al. Omega-3 poly-unsaturated fatty acids for the prevention of severe neutropenic enterocolitis in patients with acute myeloid leukemia. Nutr Cancer. 2013;65(6):834-42. doi: 10.1080/01635581.2013.801998

Sebastián Domingo JJ. Síndrome del intestino irritable. Med Clín (Barc). 2022;158(2):76-81. https://doi.org/10.1016/j.medcli.2021.04.029

Chey WD, Kurlander J, Eswaran S. Irritable Bowel Syndrome: A Clinical Review. JAMA. 2015;313(9):949-58. doi: 10.1016/j.medcli.2021.04.029

Sultan S, Malhotra A. Irritable Bowel Syndrome. Ann Intern Med. 2017;166(11):ITC81-96. doi: 10.7326/AITC201706060

Liu YL, Liu JS. Irritable bowel syndrome in China: a review on the epidemiology, diagnosis, and management. Chin Med J. 2021;134(12):1396–401. doi: 10.1097/CM9.0000000000001550

Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–73. doi: 10.3748/wjg.v20.i22.6759

Chua CS, Huang SY, Cheng CW, Bai CH, Hsu CY, Chiu HW, et al. Fatty acid components in Asian female patients with irritable bowel syndrome. Medicine. 2017;96(49):e9094. doi: 10.1097/MD.0000000000009094

Solakivi T, Kaukinen K, Kunnas T, Lehtimäki T, Mäki M, Nikkari ST. Serum fatty acid profile in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2011;46(3):299–303. doi: 10.3109/00365521.2010.533380